There are currently 239 clinical trials in Boise, Idaho looking for participants to engage in research studies. Trials are conducted at various facilities, including Saint Alphonsus Cancer Care Center-Boise, Saint Luke's Cancer Institute - Boise, Saint Luke's Mountain States Tumor Institute and Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879
Recruiting
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2024
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Severe Asthma
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
All
Ages:
All
Trial Updated:
04/22/2024
Locations: St. Alphonsus Regional Medical Center, Boise, Idaho
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: St. Luke's Health System, Boise, Idaho
Conditions: Type 2 Diabetes
Register for Updates
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
Recruiting
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2024
Locations: Site 10-130, Boise, Idaho
Conditions: Atopic Dermatitis Eczema
Register for Updates
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625
Recruiting
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexa... Read More
Gender:
All
Ages:
Between 365 days and 31 years
Trial Updated:
04/20/2024
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Register for Updates
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Recruiting
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/20/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +1 locations
Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574
Recruiting
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. T... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/20/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma, Stage III Vulvar Cancer AJCC v8, Nasopharyngeal Melanoma
Register for Updates
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
NCT04402788
Recruiting
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +1 locations
Conditions: Extensive Stage Lung Small Cell Carcinoma
Register for Updates
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT04929041
Recruiting
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker ca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma
Register for Updates
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060
Recruiting
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes can... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +1 locations
Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367
Recruiting
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Study of IMPT-314 in R/R Aggressive B-cell NHL
NCT05826535
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy. Up to approximately 90 patients (30 per coho... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: St Luke's Cancer Institute, Boise, Idaho
Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Register for Updates